0001104659-26-054106
SEC filingGridAI pivoted to AI energy orchestration, narrowing net loss 64.6% to -$6.4M, but revenue remains minimal at $36.3K and going concern risk persists.
GridAI Technologies Corp. completed a transformative year, pivoting from a life sciences company to an AI energy orchestration platform following the acquisition of GridAI Corp. and the rescission of the ImmunogenX acquisition. Revenue of $36.3K was generated entirely from the new AI energy segment, while legacy biopharmaceutical operations contributed no revenue. The company's gross profit was negative $657.4K, reflecting cost of revenue exceeding sales, resulting in a gross margin of -1813.6%. Management expects to continue evaluating capital allocation between its retained life sciences activities and energy technology operations based on strategic priorities and liquidity.
The new GridAI platform targets AI data center energy orchestration—a market with no direct competitor offering an equivalent fully integrated solution, according to management. The platform is still in development, with no commercial deployments as of the filing date. Revenue generation is expected through base platform fees and performance-based fees tied to power cost optimization. The company also retains legacy biopharmaceutical assets centered on Adrulipase (a recombinant lipase for exocrine pancreatic insufficiency), but no clinical trials were conducted in FY2025, and any advancement depends on future capital. The dual-segment structure (AI energy + biotech) creates complexity but also optionality, though the biotech segment currently contributes only costs.
GridAI faces significant risks including minimal revenue, negative gross margins, going concern uncertainty, and the need for additional capital to fund operations and develop its platform. Competition in the AI energy market is driven by software functionality, scalability, interoperability, speed of deployment, regulatory expertise, customer relationships, and pricing. The company may face pricing pressure, longer sales cycles, and increased customer acquisition costs. Management expects operating expenses to evolve as resources are allocated between Adrulipase advancement and GridAI platform expansion.